Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
On Dec. 10, 2020, leading Israeli life science fund, Pontifax, announced that it has entered into a $50 million convertible Note Purchase and Security Agreement with Opiant Pharmaceuticals Inc., a specialty pharmaceutical company, that will allow Opiant to draw up to $50 million in three tranches.
Key contacts
John Bessonette
Partner, New York
Renee Yao
Special Counsel, New York
Barry Herzog
Partner, Head of Tax, US, New York
Mariya Khvatskaya
Senior Associate, New York